HX 02Alternative Names: HX02
Latest Information Update: 15 Apr 2016
At a glance
- Originator Humanyx
- Class Antibodies
- Mechanism of Action Cytokine inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Inflammation
Most Recent Events
- 15 Apr 2016 Clinical trials in Inflammation in Singapore (unspecified route) before April 2016